Table 1. Clinical, biochemical and genetic data for cohort.

	Benign Parathyroid Disease	Parathyroid Carcinoma	Entire Cohort
Gender
Male/Female	7/3	3/3	10/6
Age at Diagnosis (years)
Median	26.4	29.9	30.7
Range	18-38	31-49	18-49
Signs/Symptoms at Presentation
Psychiatric/Neurologic *	4/10 (40.0%)	3/6 (50%)	7/16 (43.8%)
Fatigue	5/10 (50.0%)	1/6 (16.7%)	6/16 (37.5%)
GastrointestinaI symptoms **	2/10 (20.0%)	3/6 (50%)	5/16 (31.3%)
Renal ***	2/10 (20.0%)	1/6 (16.7%)	3/16 (18.8%)
Bony pain	3/10 (30.0%)	4/6 (66.7%)	3/16 (18.8%)
Fractures	1/10 (10.0%)	1/6 (16.7%)	2/16 (12.5%)
Neck mass	0/10 (0%)	1/6 (16.7%)	1/16 (6.3%)
Laboratory Findings
Average total calcium §	11.7 mg/dl	13.1 mg/dl	12.2 mg/dl
Intact PTH (benign parathyroid disease)?	212.6 pg/ml	356.5 pg/ml	236.6 pg/ml
Associated Pathology
Uterine tumor	0/3 (0%)	2/3 (66.7%)	2/6 (33.3%)
Renal lesions	0/10 (0%)	3/6 (50.0%)	3/16 (18.8%)
Jaw tumor	0/10 (0%)	2/6 (12.5%)	2/16 (12.5%)
Genetics/Mutation Type
CDC73 (whole gene deletion)	3/10 (30.0%)	4/6 (66.7%)	7/16 (43.8%)
c.687_688dupAG (exon 7)	3/10 (30.0%)	2/6 (33.3%)	5/16 (31.3%)
Y552 (exon 2)	2/10 (20.0%)	0/6 (0%)	2/16 (12.5%)
R222X (exon 7)	1/10 (10.0%)	0/6 (0%)	1/16 (6.3%)
R76X (exon 2)	1/10 (10.0%)	0/6 (0%)	1/16 (6.3%)
Post-operative Complications
Hypoparathyroidism (permanent)	1/10 (10.0%)	1/6 (16.7%)	2/16 (12.5%)
Permanent recurrent laryngeal nerve injury ¶#	0/10 (0%)	0/10 (0%)	0/16 (0%)
Hematoma	0/10 (0%)	0/10 (0%)	0/16 (0%)
Follow-Up (years)
Median	2.3	7.4	3.7
Range	0.05-13.4	0.04-11.4	0.05-13.4

^*Headaches, memory loss/changes, difficulty concentrating

^**Abdominal pain, constipation, Gastroesophageal Reflux Disease (GERD)

^***Polyuria, nephrolithiasis

^§Total calcium reference range (8.5 – 10.2 mg/dl)

^?Intact PTH reference range (10 – 55 pg/ml)

^¶At initial operation.

^#1 patient had RLN injury during the 2^nd operation.